WO2022150927A1 - Dispositifs, systèmes et méthodes pour l'administration de médicaments - Google Patents
Dispositifs, systèmes et méthodes pour l'administration de médicaments Download PDFInfo
- Publication number
- WO2022150927A1 WO2022150927A1 PCT/CA2022/050057 CA2022050057W WO2022150927A1 WO 2022150927 A1 WO2022150927 A1 WO 2022150927A1 CA 2022050057 W CA2022050057 W CA 2022050057W WO 2022150927 A1 WO2022150927 A1 WO 2022150927A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- module
- delivery device
- injection assembly
- plunger
- driver
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 22
- 239000003814 drug Substances 0.000 title description 17
- 239000012530 fluid Substances 0.000 claims abstract description 112
- 238000002347 injection Methods 0.000 claims abstract description 99
- 239000007924 injection Substances 0.000 claims abstract description 99
- 230000000712 assembly Effects 0.000 claims abstract description 13
- 238000000429 assembly Methods 0.000 claims abstract description 13
- 238000004146 energy storage Methods 0.000 claims description 83
- 230000033001 locomotion Effects 0.000 claims description 35
- 239000000504 antifibrinolytic agent Substances 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 29
- 208000032843 Hemorrhage Diseases 0.000 claims description 24
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical group NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 22
- 229960000401 tranexamic acid Drugs 0.000 claims description 22
- 229940090047 auto-injector Drugs 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 description 20
- 238000005381 potential energy Methods 0.000 description 12
- -1 but not limited to Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 208000014674 injury Diseases 0.000 description 8
- 230000008733 trauma Effects 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000003314 quadriceps muscle Anatomy 0.000 description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- 208000012266 Needlestick injury Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 description 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000012826 P38 inhibitor Substances 0.000 description 1
- 101150014691 PPARA gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 208000037486 Postoperative Hemorrhage Diseases 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 229940034014 antimycobacterial agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 238000010999 medical injection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/322—Retractable needles, i.e. disconnected from and withdrawn into the syringe barrel by the piston
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
- A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2066—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/3157—Means providing feedback signals when administration is completed
Definitions
- the present disclosure generally relates to a delivery device, and more particularly to a delivery device including at least two separate injection assemblies for automatically injecting at least two fluids at different stages of operation into a target site of a subject, such as, but not limited to, a vastus lateralis intramuscular site, after activation of the medical injection device. It also relates to methods for reducing or preventing hemorrhage comprising intramuscularly administering an antifibrinolytic agent.
- An essential element for treating many life-threatening emergencies such as shock, trauma, cardiac arrest, drug overdoses, diabetic ketoacidosis, arrhythmias, bums, and status epilepticus, is rapid establishment of an IV line in order to administer drugs and fluids directly into a patient's vascular system. Whether in an ambulance by paramedics, in an emergency room by emergency specialists or on a battlefield by an Army medic, the goal is the same - quickly start an IV in order to administer lifesaving drugs and fluids. To a large degree, the ability to successfully treat most critical emergencies is dependent on the skill and luck of an operator in accomplishing vascular access.
- Autoinjectors are devices that are designed to allow one the ability to self-administer a set dose of medication intramuscularly or subcutaneously. By providing a secondary route to the patient’s systemic circulation that avoids obtaining an IV, autoinjectors circumvent many of the difficulties that IV’ s carry, especially in hectic situations described above, such as ambulance transport and military combat. Additionally, while IV lines must be placed by a trained healthcare professional, autoinjectors can be operated by members of the general public due to their simplicity and minimal risk of needlestick injuries.
- TXA tranexamic acid
- TXA is an antifibrinolytic drug that stops the breakdown of fibrin clots formed at the site of injury. In doing so, TXA causes a significant reduction in blood loss for the patient thereby decreasing patient mortality rates.
- TXA is most effective when given immediately after injury, but research has shown that TXA is only given to 3% of trauma victims within the first hour due to the difficulties of securing IV access. However, when TXA is given within an hour of the injury, it is shown to reduce deaths caused by hemorrhagic shock by one-third.
- TXA treatment that may be provided by the trauma patient themselves in the case that they do not have quick access to a trained healthcare professional is crucial to increase the chance of their survival.
- the ability for a trained healthcare professional or the trauma user to automatically inject TXA intramuscularly would significantly decrease the treatment time and increase the access to the drug without requiring an IV.
- Known devices capable of accessing an IM site and/or administering drugs intramuscularly include, for example, the devices described in:
- the present disclosure provides a delivery device operable to automatically inject and deliver at least two fluids separately to a target site of a subject during at least two different stages of operation comprising: a lower body configured to house at least two injection assemblies; an upper body configured to move over the lower body in a longitudinal direction upon application of a force to the upper body; a first injection assembly positioned within the lower body; a second injection assembly positioned within the lower body adjacent to the first injection assembly; and a movable setting switch operable to select the first injection assembly or the second injection assembly.
- the first injection assembly and second injection assembly each comprise: an actuator operable for activating the injection assembly; a plunger module moveable between a first position and second position, a first releasable retainer member configured to secure the plunger module in the first position and release the plunger module after activation of the injection assembly, a first energy storage member operable to release energy to the plunger module and displace the plunger module in a proximal direction from the first position to the second position, a fluid container configured to hold a fluid and having a distal end configured to receive the plunger module and a proximal end with an outlet, a driver moveable from a first position to a second position having a proximal end and a distal end, the driver and fluid container operatively coupled at the driver’s distal end and the fluid container’s proximal end, a second energy storage member operable to release energy to the driver and displace the driver in a proximal direction, a needle module moveable between a first position and second position and having
- the present disclosure provides a method for reducing or preventing hemorrhage, comprising intramuscularly administering an antifibrinolytic agent in a dose of 0.1 g to 30 g at a rate of no less than 50 mg/s.
- the present disclosure provides a method for reducing or preventing hemorrhage, comprising intramuscularly administering an antifibrinolytic agent with an autoinjector in a dose of 0.1 g to 30 g.
- the present disclosure provides use of an antifibrinolytic agent for reducing or preventing hemorrhage, wherein the agent is administered intramuscularly in a dose of about 0.1 g to about 30 g at a rate of no less than 50 mg/s.
- the present disclosure provides use of an antifibrinolytic agent for reducing or preventing hemorrhage, wherein the agent is administered intramuscularly with an autoinjector in a dose of about 0.1 g to about 30 g.
- the present disclosure provides a delivery device operable to automatically inject and deliver at least two fluids comprising at least 0.1 grams of an antifibrinolytic agent separately to a target site of a subject during at least two different stages of operation comprising: a lower body configured to house at least two injection assemblies; an upper body configured to move over the lower body in a longitudinal direction upon application of a force to the upper body; a first injection assembly positioned within the lower body; a second injection assembly positioned within the lower body adjacent to the first injection assembly; and a movable setting switch operable to select the first injection assembly or the second injection assembly.
- FIG. 1A is a cross-sectional view of a delivery device according to one embodiment in a first configuration
- FIG. IB is a cross-sectional view of the delivery device of FIG. 1A in a second configuration
- FIG. 1C is a cross-sectional view of the delivery device of FIG. 1A in a third configuration
- FIG. ID is a cross-section view of the delivery device of FIG. 1A in a fourth configuration
- FIG. 2 is an exploded view of a delivery device according to an embodiment of the present disclosure
- FIG. 3 is a cross-sectional view of the delivery device of FIG. 2 in a first configuration
- FIG. 4 is a cross-sectional view of the delivery device of FIG. 2 in a second configuration
- FIG. 5 is a cross-sectional view of the delivery device of FIG. 2 in a third configuration and;
- FIG. 6 is a perspective view of the delivery device of FIG. 2 in a first configuration.
- a container means one container or more than one container.
- the phrases “in one embodiment”, “according to one embodiment” and the like generally mean the particular feature, structure, or characteristic following the phrase is included in at least one embodiment of the present disclosure, and may be included in more than one embodiment of the present disclosure. Importantly, such phrases do not necessarily refer to the same aspect. If the specification states a component or feature “may”, “can”, “could”, or “might” be included or have a characteristic, that particular component or feature is not required to be included or have the characteristic.
- proximal and distal refer to directions closer to and away from, respectively, the desired position of injection and delivery of fluid of the delivery device.
- the words “upward”, “downward”, “upper”, “lower”, “right” and “left” designate directions in the drawings to which reference is made.
- the words “inward” and “outward” refer to directions toward and away from, respectively.
- IM site refers to a position where an injection of a fluid can be administered into any muscle of a subject, such as the deltoid, vastus lateralis, rectus femoris, or the ventrogluteal and dorsogluteal areas.
- movably coupled means that one member is directly or indirectly supported by another member to allow movement of the one member.
- operatively coupled can refer to a direct or indirect coupling engagement between two or more structural component parts.
- fluid includes any liquid, such as but not limited to, blood, water, saline solutions, IV solutions or plasma, or any mixture of liquids, particulate matter, medicament, dissolved medicament and/or drugs appropriate for injection into the target site of a subject.
- container refers to a pharmaceutically acceptable container comprising a chamber suitable to house a fluid.
- Containers can include, but are not limited to vials, barrels, ampoules or bottles and in some embodiments are made of glass, plastic, composites, laminates or metal.
- a “subject” may be a human or non-human mammal.
- Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine and feline mammals.
- the subject is a human and in some embodiments the operator and the subject are the same (i.e. the delivery device is a self-administering delivery device).
- embodiments of the present disclosure are generally directed to a delivery device adapted to automatically inject and deliver at least two fluids separately into a target site, such as an IM site, of a subject during at least two different stages of operation.
- the delivery device is sized to be carried in compact spaces such as, but not limited to, military pouches and tactical vests.
- the delivery device 1 includes a lower body 4 which is configured to house at least two injection assemblies (i.e. a first and second injection assembly 2 and 2’), each injection assembly configured to inject and deliver a fluid to the IM site of the subject.
- each injection assembly is configured to inject and deliver at least 1 mL or at least 2 mL or at least 3 mL or at least 4 mL or at least 5 mL of the fluid to the IM site of the subject.
- the delivery device 1 may include three or more injection assemblies.
- Lower body further includes a first stop 14 and a second stop 24 which is described further below.
- the delivery device 1 also includes an upper body 3 which is movably coupled to the lower body 4.
- the upper body 3 is configured to be moveable over the lower body 4 in a longitudinal direction L upon application of a force to the upper body 3.
- the upper body 3 may also include a setting switch 3a moveably coupled thereto in a horizontal direction for the purpose of selecting the desired injection assembly for use.
- the injection assembly 2 generally includes an actuator 5 to activate the injection assembly 2, a plunger module 8 moveable between a first position and second position, a first releasable retainer member 6 configured to secure the plunger module 8 in the first position and release the plunger module 8 after activation of the injection assembly 2, a first energy storage member 7 operable to release energy to the plunger module 8 and displace the plunger module 8 in the proximal direction from the first position to the second position, and a fluid container 9 having a distal end configured to receive the plunger module 8 and a proximal end with an orifice or outlet.
- the plunger module 8 is sized to be movably disposed within the fluid container 9.
- the fluid container 9 is configured to hold the fluid.
- the fluid comprises a medicament, such as, for example, tranexamic acid or any of the other medicaments further described below.
- the injection assembly 2 also includes a driver 11 moveable from a first position to a second position and having a proximal end and a distal end.
- the driver 11 and fluid container 9 are operatively coupled at the driver’s distal end and the fluid container’s proximal end.
- the injection assembly 2 also includes a second energy storage member 10 operable to release energy to the driver 11 and displace the driver 11 in a proximal direction.
- the first stop 14, which is positioned near the proximal end of the lower body 4, is sized and configured to stop movement of the driver 11 in a proximal direction when the driver’s proximal end contacts the stop 14.
- the injection assembly 2 also includes a needle module 12 moveable between a first position and second position and having a distal end in fluid communication with the outlet of the fluid container 9 and a proximal end for insertion into the IM site and delivering fluid to the subject.
- the injection assembly 2 also includes a second releasable retainer member 6a configured to secure the needle module 12 to the driver 11 in the first position and to release the needle module 12 when the plunger module 8 is located at its second position.
- the injection assembly 2 includes a return energy storage member 13 operable to release energy to the needle module 12 and displace the needle module 12 in a distal direction from the first position to the second position after the needle module 12 has been released from the driver 11.
- the delivery device 1 further includes at least a second injection assembly 2’ .
- the injection assembly 2’ generally includes an actuator 15, a first energy storage member 17, a plunger module 18, a first releasable retainer member 16, a fluid container 19 (configured to hold a fluid which may be the same as or different from the fluid in fluid container 9 in the volumes above), a driver 21 (lower body 4 includes a second stop 24 to prevent movement of the driver 21 in the proximal direction once the driver 21 contacts second stop 24), a needle module 22, a second energy storage member 20, a second releasable retainer member 16a and a return energy storage member 23.
- the components of the second injection assembly 2’ are arranged and operate similarly to those of the first injection assembly 2. Accordingly, the description of the first injection assembly’s components, their arrangement and operation will apply to the second injection assembly 2’.
- the delivery device 1 can generally be operated by moving the setting switch 3a to select the desired injection assembly for use, for example injection assembly 2 as shown in FIG. 1A, and applying a force to the upper body 3 in the proximal direction to move the upper body 3 in a proximal direction over at least a portion of the lower body 4 which activates the actuator 5.
- Activation of actuator 5 causes an automatic sequence of movements.
- the plunger module 8 is released from the first releasable retainer member 6 and displaced in a proximal direction by the first energy storage member 7.
- the driver 11, fluid container 9, needle module 12 and second releasable retainer member 6a are also displaced in the proximal direction by the second energy storage member 10 until movement in the proximal direction is prevented by the engagement of driver 11 with stop 14. Movement of the plunger module 8 in the proximal direction will continue until reaching the second position at the distal end of the fluid container 9. Accordingly, it will be in cooperative engagement with the fluid container 9 and second releasable retainer member 6a at its second position.
- the first energy storage member 7 is operable to continue to apply energy to the plunger module 8 that is sufficient to movably displace the second releasable retainer member 6a (but not the fluid container 9 since its movement is prevented by driver 11 and stop 14) in a proximal direction. Such movement by the second releasable retainer member 6a releases the needle module 12 from the driver 11. The needle module 12 is then displaced in the distal direction by the return energy storage member 13. [0040] It should be noted that when the setting switch 3a is located over the second injection assembly 2’, activation of actuator 15 will begin a similar automatic sequence of movements since the components of the second injection assembly 2’ and their arrangement and operation are similar to those of the first injection assembly 2.
- the delivery device 1 is shown in a first configuration and a second configuration.
- the upper body 3 is displaced over the lower body 4, as indicated by arrow A in FIG. IB, along a longitudinal axis L between a first position (FIG. 1A) and a second position (FIG. IB).
- the setting switch 3a is also displaced in the proximal direction from a first position to second position which activates actuator 5.
- the actuator 5 may be any suitable device for activating the delivery device 1, such as, for example, a handle, a lever, a push button, a slidable button or a trigger.
- the plunger module 8 Prior to activation, the plunger module 8 is held in a secure position by the first releasable retainer member 6.
- the first releasable retainer member 6 is configured to release the plunger module 8 and deploy the first energy storage member 7 from its first configuration to second configuration after the actuator 5 has been activated by the movement of the upper body 3 and setting switch 3a in the proximal direction from their first position to second position.
- the first releasable retainer member 6 can be any suitable mechanism for releasably retaining the plunger module 8 and deploying the first energy storage member 7, such as, for example, a mechanical linkage, a compressed ring, a spring-loaded rod, a tensioned latch or tab or a gear collar/helical plunger mechanism (which uses static friction to hold the plunger module before releasing it) or the like.
- the second energy storage member 10 Upon activation of the actuator 5 and release of the plunger module 8 by the first releasable retainer member 6, the second energy storage member 10 is deployed from its first configuration to second configuration.
- the fluid container 9 and driver 11 are operatively coupled and each move in a proximal direction, as indicated by arrow A in FIG. IB, along a longitudinal axis L from a first position (FIG. 1A) to second position (FIG. IB) by second energy storage member 10 where further movement in the proximal direction is prevented by stop 14.
- the needle module 12 is still held in a secure position to the driver 11 by the second releasable retainer member 6a and both remain in their first position.
- the needle module 12 is positioned entirely within the lower body 4.
- the fluid container 9 and driver 11 have been displaced (or advanced) to the second position by the second energy storage member 10 and at least a portion of the needle module 12 extends outside the lower body 4 for insertion into the target site of the subject at a desired depth.
- movement of the delivery device 1 from the first configuration to second configuration will extend a portion of the needle module 12 outside of the lower body 4 for insertion into, for example, the IM site of the subject.
- the plunger module 8 is further displaced in a proximal direction, as indicated by arrow B, along a longitudinal axis L between a first position (FIG. 1A) and second position (FIG. 1C) by deployment of the first energy storage member 7.
- a portion of the plunger module 8 at its proximal end is positioned at the distal end of the fluid container 9.
- the plunger module 8 is in fluid communication with the fluid contained within fluid container 9.
- the plunger module 8 When the plunger module 8 is displaced (or advanced) to the second position, the plunger module 8 is advanced from the distal end of the fluid container 9 to the proximal end of the fluid container 9. In this manner, as the plunger module 8 is displaced (or advanced) between the first and second positions, fluid is conveyed from within fluid container 9 through the needle module 12 and into the IM site of the subject. Thus, movement of the delivery device 1 from the second configuration to third configuration delivers fluid into the IM site of the subject.
- FIG. ID which depicts the delivery device 1 in a fourth configuration
- the needle module 12 is held in a secure position to the driver 11 by the second releasable retainer member 6a.
- the second releasable retainer member 6a is configured to release the needle module 12 and deploy the return energy storage member 13 from its first configuration to second configuration once the plunger module 8 reaches its second position.
- the second releasable retainer member 6a can be any suitable mechanism for releasably retaining the needle module 12 and deploying the return energy storage member 13, such as, for example, a mechanical linkage, a compressed ring, a spring-loaded rod, a tensioned latch or tab or the like.
- the return energy storage member 13 Upon release of the needle module 12 by the second releasable retainer member 6a, the return energy storage member 13 is also deployed from its first configuration to second configuration. Energy released from the return energy member 13 to the needle module 12 displaces the needle module 12 in a distal direction, as indicated by arrow C in FIG. ID, along a longitudinal axis L between a first position (FIG. 1C) and second position (FIG. ID) within the proximal end of the fluid container 9 and is fully retracted back into the lower body 4. The setting switch 3a can then be moved in a horizontal direction to select the second injection assembly 2’ for use.
- movement of the delivery device 1 from the third configuration to fourth configuration fully retracts the needle module 12 back into the lower body 4 and readies the delivery device 1 for the second insertion and delivery of a second fluid by the second injection assembly 2’.
- the operator may then repeat the previous steps to insert and deliver the second fluid from the second injection assembly 2’ to the same or different IM site.
- the first, second and return energy storage members 7, 10 and 13 each independently can be any device for storing energy.
- one or more of the first, second and return energy storage members 7, 10 and 13 may be a mechanical energy storage member, such as a spring, a device containing compressed gas, a device containing a vapor pressure-based propellant or the like or an electrical energy storage member, such as a battery, a capacitor, a magnetic energy storage member or the like.
- one or more of the first, second and return energy storage members 7, 10 and 13 can be a chemical energy storage member, such as a container containing two substances that, when mixed, react to produce energy.
- each energy storage member defines a longitudinal axis L.
- the first energy storage member 7 can be moved within the lower body 4 along L between a first configuration (FIG. 1A) and a second configuration (FIG. 1C).
- first energy storage member 7 When the first energy storage member 7 is in its first configuration, it has a first potential energy.
- first energy storage member 7 When the first energy storage member 7 is in its second configuration, it has a second potential energy that is less than the first potential energy.
- the first energy storage member 7 is operably coupled to the plunger module 8 such that when the first energy storage member 7 moves from its first configuration to its second configuration, it converts at least a portion of its first potential energy into kinetic energy to displace the plunger module 8 in the proximal direction from its first position to second position.
- the movement of the first energy storage member 7 from its first configuration to its second configuration results in the release of energy that acts upon the plunger module 8 to move the plunger module 8 from its first position to second position and thereby dispense fluid contained within the fluid container 9.
- the energy released is also sufficient to displace the second releasable retainer member 6a from its first position to second position when the plunger module is in its second position and release the needle module 12 from driver 11.
- the second energy storage member 10 can be moved within the lower body 4 along L between a first configuration (FIG. 1A) and a second configuration (FIG. IB).
- a first configuration FIG. 1A
- a second configuration FIG. IB
- the second energy storage member 10 When the second energy storage member 10 is in its first configuration, it also has a first potential energy.
- the second energy storage member 10 When the second energy storage member 10 is in its second configuration, it has a second potential energy that is less than the first potential energy.
- the second energy storage member 10 is operably coupled to the driver 11 such that when the second energy storage member 10 moves from its first configuration to its second configuration, it converts at least a portion of its first potential energy into kinetic energy to displace the driver 11 and fluid container 9 which is operatively coupled to the driver 11 in the proximal direction from their first position and second position (needle module 12 which is secured to the driver 11 by the second releasable retainer member 6a in its first position also moves with the driver 11).
- the movement of the second energy storage member 10 from its first configuration to its second configuration results in the release of energy that acts upon driver 11 and fluid container 9 to move them from their first position to second position at stop 14.
- the needle module 12 which is secured to the driver 11 by the second releasable retainer member 6a partially extends outside the lower body 4 as the driver moves between its first and second position to insert into the target site of the subject at the desired depth (i.e. depending upon where the stop 14 is positioned and/or the length of the needle module 12).
- the return energy storage member 13 can be moved within the lower body 4 along L between a first configuration (FIG. 1A) and a second configuration (FIG. ID).
- a first configuration FIG. 1A
- a second configuration FIG. ID
- the return energy storage member 13 is operably coupled to the needle module 12 such that when the return energy storage member 13 moves from its first configuration to its second configuration, it converts at least a portion of its first potential energy into kinetic energy to move the needle module 12 from its first position to second position in a distal direction.
- the delivery device 100 generally includes a lower body 110 and an upper body 120 movably coupled to the lower body 110.
- the lower body 110 is generally shaped and dimensioned to fit within an operator’s hand and includes a distal end 110a, a proximal end 110b and an exterior surface 111.
- the lower body 110 may be a unitary structure (i.e., one-piece) that defines the exterior surface 111, or it may include a plurality of layers with different layers defining the exterior surface 111.
- the lower body 110 may further include a safety switch 112 movably coupled thereto which may be operated by the operator and an opening 113 to accommodate the safety switch 112.
- the safety switch 112 is adapted and configured to prevent the premature or accidental activation of the delivery device 100.
- the safety switch 112 shown in FIG. 6 is a lever in engagement with the opening 113 and the lower slot 126 of upper body 120 and must be turned counter clockwise to release it from engagement, but it may also be a switch, a button, or similar mechanism to prevent accidental activation.
- the lower body 110 may be rigid. According to other embodiments, the lower body 110 may be flexible, whether according to the nature of the material that defines the lower body 110 or according to the nature of the structure of the lower body 110.
- the lower body 110 may be made of glass, metal, or polymer, for example.
- polymer versions may be made of polycarbonate, polypropylene, polyethylene (such as high density polyethylene), polytetrafluoroethylene, cyclic olefin polymer, cyclic olefin copolymer, crystal zenith olefinic polymer, nylon, or engineering resins.
- the lower body 110 further houses two chambers 114 and 116 that extend from the distal end 110a to the proximal end 110b of the lower body 110 and that are sized and configured to support injection assembly 102 and 104, respectively. Although two chambers and two injection assemblies are shown, the lower body 110 may include more than two chambers for holding more than two injection assemblies if desired.
- Chamber 114 includes an opening at its distal end 114a and proximal end 114b.
- chamber 116 includes an opening at its distal end 116a and proximal end 116b. Such openings may include a breakable or removable seal or cover (not shown) for sterilization purposes prior to use. Chambers 114 and 116 also include stops 115 and 117 which are sized and configured to engage the driver 170 and prevent movement of the driver 170 in the proximal direction as will be described below.
- the upper body 120 includes a distal end 120a and a proximal end 120b and is generally shaped and dimensioned to be slidably disposed over the lower body 110 in a proximal direction from a first position to a second position upon application of a force in the proximal direction and in a distal direction from the second position to the first position upon application of a force in the distal direction.
- the upper body 120 includes an exterior surface 121.
- the upper body 120 may be a unitary structure (i.e., one-piece) that defines the exterior surface 121, or it may include a plurality of layers with different layers defining the exterior surface 121.
- the upper body 120 may further include a setting switch 122 movably coupled thereto which may be operated by the operator and an opening 123 to accommodate the setting switch 122.
- Opening 123 is configured to allow the setting switch 122 to be movably displaced in a horizontal direction due to the presence of two opposing rails 123a and 123b positioned on the walls of the opening 123.
- the rails 123a and 123b lead into internal stop ends 123c and 123d limiting the distance the setting switch 122 can travel in the horizontal direction within the opening 123.
- the setting switch 122 may include a ridge 122a on its lower surface which is sized and configured to activate actuator 130 when a force is applied to move the upper body 120 in a proximal direction, thus activating a sequence of movements for an injection assembly to inject and deliver a first fluid to the target site of the subject. Once the delivery of the first fluid to the subject has been completed, the operator may move the setting switch 122 to the opposite stop end to position the setting switch 122 over the other injection assembly for insertion into the same or different target site and delivery of a second fluid to the subject.
- the upper body 120 may further include a landmarking system 125 for the purpose of indicating where the chambers 114 and 116, and therefore the injection assemblies 102 and 104, are positioned.
- the landmarking system 125 includes markings on the exterior surface 121 of the upper body 120 such that the operator can visually determine the location of the injection assemblies relative to the anatomical features of the subject.
- the upper body 120 may also include lower slot 126 to accommodate and engage the safety switch 112 of lower body 110 to prevent accidental activation.
- upper body 120 may feature one more elongated windows (not shown) sized and configured to allow the operator to view the contents within the lower body 110, and in particular, the chambers 114 and 116.
- the windows may be covered with a clear material, such as a translucent or transparent material, to maintain sterility of the delivery device 100 while allowing the operator to view the contents of the lower body 110.
- the windows may be any suitable shape for viewing the contents, such as, but not limited to, an arrow or a long oval.
- the delivery device 100 includes a first injection assembly 102 and a second injection assembly 104 positioned within chambers 114 and 116 of lower body 110. The components for each injection assembly and their arrangement and operation are similar and accordingly only the first injection assembly 102 will be described below.
- the first injection assembly 102 includes an actuator 130, a first releasable retainer member 132, a first energy storage member 134, a plunger module 140, a fluid container 150, a second energy storage member 152, a second releasable retainer member 154, a return energy storage member 156, a needle module 160 and a driver 170.
- actuator 130 in the form of a slidable button having an opening at its proximal end with an expanded inner cavity 131, is positioned at the distal end 114a of chamber 114.
- the actuator 130 is shown in a first position in FIG. 3 and is advanced in the proximal direction to its second position shown in FIG. 4 by movement of the upper body 120 and setting switch 122 from their first position shown in FIG. 3 to second position shown in FIG. 4 during operation of the delivery device 100.
- movement by the actuator 130 from its first position to second position activates the delivery device 100 to cause a sequence of movements of the injection assembly 102 that subsequently leads to the injection and delivery of fluid contained within the injection assembly 102.
- the first releasable retainer member 132 engages the surface of the opening at the proximal end of the actuator 130 and the exterior surface 141 of the plunger module 140.
- the first releasable retainer member 132 is inherently biased outwardly, with the exterior surface 141 of the plunger module 140 being shaped and configured so as to interferingly engage the first releasable retainer member 132 under force of movement of the first energy storage member 134 when the delivery device 100 is in the initial position (first configuration).
- the opening of the proximal end of the actuator 130 is shaped and configured so as to interferingly engage the first releasable retainer member 132 when the delivery device 100 is in the first configuration.
- the injection assembly 102 may further include a safety activation mechanism operatively coupled with actuator 130 which prevents the actuator 130 from moving in a proximal direction thus preventing the first releasable retainer member 132 from moving into the expanded inner cavity 131 of actuator 130 and releasing the plunger module 140 from engagement until the safety activation mechanism is activated.
- safety activation mechanism is configured to prevent the premature or accidental deployment of the delivery device 100.
- the safety activation mechanism can be comprised of any suitable mechanism, such as an energy storage member described above, a button, a pin, or similar mechanism. In such embodiments, once the safety switch 112 is released from engagement, the safety activation mechanism will prevent the actuator 130 from activation until the safety activation mechanism is activated.
- the safety activation mechanism therefore acts as a second safety mechanism and will prevent the premature or accidental activation of the delivery device irrespective of the release of safety switch
- the injection assembly 102 also includes a fluid container 150.
- the fluid container 150 is configured to hold a fluid.
- the fluid container 150 includes an open distal end 150a and a proximal end 150b comprising an outlet or orifice that is fluidly coupled to the needle module 160, such as by a luer connector, threads, a snap-fit, a latch, a lock, a friction fit coupling, an adhesive or any other suitable coupling features (not shown).
- the fluid container 150 may have a length of between about 10 millimeters (mm) to about 70 mm.
- the distal end 150a and proximal end 150b may have a diameter of between about 10 mm to about 25 mm.
- the orifice at the proximal end 150b may have a diameter of between about 0.05 mm to about 1.6 mm.
- the fluid container 150 defines an internal volume configured to house a fluid.
- the fluid container 150 may be configured to hold an amount of fluid in the range of about 1 milliliter (mL) to about 20 mL, or about 2 mL to about 15 mL, or about 3 mL to about 10 mL, or about 4 mL to about 6 mL.
- the fluid may comprise a medicament such as, but not limited to, an analgesic, anti-inflammatory agent, anthelmintic, anti- arrhythmic agent, antibiotic (including penicillin), anticoagulant, antidepressant, antidiabetic agent, antiepileptic, antihistamine, antihypertensive agent, antimuscarinic agent, antimycobacterial agent, antineoplastic agent, antifibrinolytic, immunosuppressant, antithyroid agent, antiviral agent, anxiolytic sedative (hypnotics and neuroleptics), astringent, beta-adrenoceptor blocking agent, blood product and substitutes, cardiac inotropic agent, corticosteroid, cough suppressant (expectorants and mucolytics), diagnostic agent, diuretic, dopaminergic (antiparkinsonian agents), haemostatic, immunological agent, lipid regulating agent, muscle relaxant, parasympathomimetic, parathyroid calcitonin and biphosphonate, prostaglan
- the injection assembly 102 also includes a first energy storage member 134.
- the first energy storage member 134 is a mechanical energy storage member comprising a spring, such as, for example, a helical, compression, extension, torsion, constant, variable, variable stiffness or any other type of spring having a spring constant ranging between about 1 N/m to about 500 N/m.
- the first energy storage member 134 is operatively coupled to the plunger module 140 and releases energy to the plunger module 140 to displace the plunger module 140 in the proximal direction when the first energy storage member 134 moves from its first configuration to second configuration after the actuator 130 has been activated.
- the plunger module 140 comprises a plunger rod 142, a plunger tip 144 movably coupled to the plunger rod 142 and a plunger seal 146.
- the plunger module 140 may be formed as a single piece or as modular components. The modular components may be affixed to one another or located adjacently, but not connected, so as to move together.
- the plunger module 140 is sized and configured to be movably disposed within the fluid container 150 when it moves between its first position and second position.
- the plunger rod 142 is shown as a cylindrical body having a distal end 142a, a proximal end 142b, an exterior surface 143 and an inner cavity 143a.
- the inner cavity 143a may extend from the plunger rod’s distal end 142a towards the proximal end 142b for a distance that is less than the length of the plunger rod 142, although in some embodiments it may extend for a distance equal to about the length of the plunger rod 142.
- the plunger rod 142 further includes an upper rim 145a and a lower rim 145b.
- the plunger module 140 and first energy storage member 134 are operatively coupled at upper rim 145a.
- the lower rim 145b is positioned inside of fluid container
- the plunger tip 144 is located at the proximal end 142b of plunger rod 142 in a first position.
- the plunger tip 144 is sized and configured to move in a distal direction within inner cavity 143a to a second position when the needle sleeve 162 is displaced from its first position to second position by the energy released from the return energy storage member 156 as it moves from its first configuration to second configuration as will be described below.
- the proximal end 142b of the plunger rod 142 can be coupled to and/or in contact with the plunger seal 146 which is configured to be in fluid communication with the fluid disposed within the internal volume defined by the fluid container 150.
- the proximal end 142b of the plunger rod 142 is configured to be movably displaced within the internal volume defined by the fluid container 150 by the energy released by the first energy storage member 134 when the first energy storage member 134 moves from its first configuration to second configuration. In this manner, the first energy storage member 134 acting on the plunger rod 142 can displace the plunger seal 146 within the fluid container 150 to expel the fluid through the orifice at proximal end 150b of fluid container 150.
- the sidewalls of the plunger seal 146 can be configured to contact the interior surfaces of the sidewalls of the fluid container 150 such that the plunger seal 146 forms a fluid-tight seal with the sidewalls of the fluid container 150, for example, to prevent leakage of the fluid.
- the plunger seal 146 can be made of an inert and/or biocompatible material which is rigid but soft. Example materials include rubber, silicone, plastic, polymers, any other suitable material or combination thereof.
- the plunger seal 146 can be monolithically formed with the plunger module 140.
- the plunger module 140 may also include one-way bendable tabs (not shown) to prevent movement of the plunger rod 142 in the distal direction once the plunger module 140 has advanced to the second position.
- the injection assembly 102 includes driver 170.
- the driver 170 is shown as a cylindrical plug having a distal end 170a and a proximal end 170b and is sized and configured to be movably disposed within chamber 114 in a proximal direction from a first position to a second position.
- the driver 170 further includes an inner cavity 171 sized and configured to support the needle module 160.
- the inner cavity 171 further includes an expanded region 172.
- the driver 170 also includes groove 173 at its distal end 170a that is sized and configured to hold and support the fluid container 150. The driver 170 and fluid container 150 are therefore operatively coupled.
- the injection assembly 102 also includes a second energy storage member 152.
- the second energy storage member 152 is a mechanical energy storage member comprising a spring, such as, for example, a helical, compression, extension, torsion, constant, variable, variable stiffness or any other type of spring having a spring constant ranging between about 1 N/m to about 500 N/m.
- the second energy storage member 152 is operatively coupled to the driver 170 at distal end 170a and releases energy to the driver 170 to displace the driver 170 when the second energy storage member 152 moves from its first configuration to second configuration after the actuator 130 has been activated.
- the injection assembly 102 also includes a second releasable retainer member 154 which secures the needle module 160 to the driver 170 at a first position and is configured to release the needle module 160 when the plunger module 140 moves to its second position.
- the second releasable retainer member 154 engages the surface of the inner cavity 171 of driver 170 and the exterior surface of the needle module 160.
- the second releasable retainer member 154 is inherently biased outwardly, with the exterior surface of the needle module 160 being shaped and configured so as to interferingly engage the second releasable retainer member 154 under force of movement of the return energy storage member 156.
- the second releasable retainer member 154 will then move from a first position to a second position within the expanded region 172 of inner cavity 171 thus allowing it to spring outwards thereby releasing the needle module 160 from engagement with driver 170 (i.e.
- the energy released from the first energy member 134 is translated to the second releasable retainer member 154 when the plunger module 140 is displaced to its second position, the energy being sufficient to displace the second releasable retainer member 154 in a proximal direction from a first position to a second position).
- the injection assembly 102 also includes a needle module 160.
- the needle module 160 includes a needle sleeve 162 affixed to a needle 164 operable for intramuscular injection.
- the needle sleeve 162 is configured to be displaced in the distal direction when released from engagement with the driver 170 by movement of the second releasable retainer member 154 from its first position to second position.
- the needle sleeve 162 will be in cooperative engagement with driver 170 and move in a proximal direction with driver 170 as driver 170 moves from its first position to second position and will be released from the driver 170 when the second releasable retainer member 154 moves from its first position to second position.
- the needle sleeve 162 and needle 164 are sized to be movably disposed within the inner cavity 143a of the plunger module 140 as will be described below.
- the needle module 160 may further include a needle cover (not shown).
- the needle cover is configured to prevent needlestick injuries and maintain the sterility of the needle 164 by providing a protective barrier around the needle 164.
- the needle cover can be manually removed before operation of the delivery device 100 or may be operable to automatically remove itself during the insertion of needle 164 into the subject then and re-cover the needle 164 after retraction of the needle 164.
- the injection assembly 102 also includes a return energy storage member 156.
- the return energy storage member 156 is a mechanical energy storage member comprising a spring, such as, for example, a helical, compression, extension, torsion, constant, variable, variable stiffness or any other type of spring having a spring constant ranging between about 1 N/m to about 500 N/m.
- the return energy storage member 156 may be a mechanical linkage, a spring- loaded rod, a tensioned latch or tab or collet / conical taper mechanism which utilizes static friction.
- the return energy storage member 156 is operatively coupled to the needle sleeve 162 and releases energy to the needle sleeve 162 to move it in a distal direction from its first position to second position when the return energy member 156 moves from its first configuration to second configuration (which is after the second releasable retainer member 154 has moved from its first position to second position to release the needle sleeve 162 from the driver 170).
- FIGS. 3-5 To illustrate operation of the delivery device 100, a sequence of events illustrating the injection and delivery of fluid by the device 100, as well as the position of the various components, is discussed progressing from FIGS. 3-5.
- FIG. 3 illustrates the delivery device 100 in an initial position (i.e. first configuration), where the delivery device 100 is ready for use and activation.
- Upper body 120 is in a first position.
- Setting switch 122 is in a first position and located over injection assembly 102 and chamber 114.
- Actuator 130 is in its first position.
- First, second and third energy storage members 134, 152 and 156 are in their first configurations.
- the plunger module 140 is held in place by the first releasable retainer member 132, the first releasable retainer member 132 being in tension between the plunger rod 142 and the actuator 130.
- the driver 170 and fluid container 150 are cooperatively engaged and in their first position.
- the needle module 160 is held in place within driver 170 by the second releasable retainer member 154, the second releasable retainer member 154 being in tension between the needle sleeve 162 and driver 170.
- the needle 164 is fully within lower body 110.
- the landmarking system 125 on the exterior surface 121 of the upper body 120 may be used to place the injection assembly that is to be used over the desired target site, such as an IM site (for e.g. the vastus lateralis muscle) of the subject. Once the desired point of insertion is determined, the activation of the delivery device 100 can begin.
- FIG. 4 illustrates the delivery device 100 in a second configuration.
- a 2-step activation mechanism may be required to activate the actuator 130.
- the safety switch 112 shown in FIG. 6
- the safety activation mechanism which is configured to oppose the downward motion of the upper body 120 is released from engagement.
- activation may be a 1-step activation where either the safety switch 112 or safety activation mechanism is present and must be released, while in still other embodiments the delivery device 100 does not include the safety switch 112 or safety activation mechanism.
- the delivery device 100 can be activated by applying a force in the proximal direction to the upper body 120 to move the upper body 120 and setting switch 122 in the proximal direction from their first position to second position and to move the actuator 130 from its first to second position.
- the first releasable retainer member 132 expands in the inner cavity 131 of the actuator 130 to release the plunger module 140.
- Energy from the first energy storage member 134 as it moves from its first configuration to second configuration is released to the plunger module 140 to begin its movement in the proximal direction within the fluid container 150 towards its second position.
- FIG. 5 illustrates the delivery device 100 in a third configuration.
- the plunger module 140 has further moved in the proximal direction within fluid container 150 to its second position to deliver substantially all of the fluid within the fluid container 150 to the needle 164 and into the subject.
- the proximal end of the plunger module 140 (plunger tip 144 and plunger seal 146) is now in cooperative engagement with the second releasable retainer member 154.
- Energy released by the first energy storage member 134 to the plunger module 140 is transferred to the second releasable retainer member 154 in an amount that is sufficient to move the second releasable retainer member 154 from its first position to second position to release the needle sleeve 162 from engagement with the driver 170.
- the delivery device 100 may also include a component for providing feedback to the operator once the injection and delivery of fluid is complete and the needle 164 has been fully retracted back into the lower body 110, such as, but not limited to, a viewing window indicating that the injection and delivery of fluid has been completed or an audible click.
- a component for providing feedback to the operator once the injection and delivery of fluid is complete and the needle 164 has been fully retracted back into the lower body 110 such as, but not limited to, a viewing window indicating that the injection and delivery of fluid has been completed or an audible click.
- embodiments of the present disclosure are directed to a method for reducing or preventing hemorrhage, comprising intramuscularly administering an antifibrinolytic agent in a dose of about 0.1 g to about 30 g at a rate of no less than 50 mg/s; or use of an antifibrinolytic agent for reducing or preventing hemorrhage, wherein the agent is administered intramuscularly in a dose of about 0.1 g to about 30 g at a rate of no less than 50 mg/s.
- the dose is administered at a rate of no less than 100 mg/s, no less than 150 mg/s, or no less than 200 mg/s, or no less than 250 mg/s. In some embodiments, the dose is administered at a rate of about 250 mg/s. In some embodiments, the dose is administered within about 5 seconds, within about 10 seconds, or within about 15 seconds. In some embodiments, the dose is administered within about 10 seconds.
- embodiments of the present disclosure are directed to a method for reducing or preventing hemorrhage, comprising intramuscularly administering an antifibrinolytic agent with an autoinjector in a dose of about 0.1 g to about 30 g; or use of an antifibrinolytic agent for reducing or preventing hemorrhage, wherein the agent is administered intramuscularly with an autoinjector in a dose of about 0.1 g to about 30 g.
- the autoinjector a multi-dose autoinjector.
- the antifibrinolytic agent is tranexamic acid (TXA) or e- aminocaproic acid (EACA). In some embodiments, the antifibrinolytic agent is TXA. In some embodiments, the antifibrinolytic agent is EACA.
- the dose is about 0.1 g to about 20 g, about 0.1 g to about 10 g, about 0.1 g to about 5 g, about 0.1 g to about 4 g, about 0.1 g to about 3 g, about 0.1 to about 2 g, about 0.1 to about 1.5 g, about 0.1 g to about 1 g, about 0.5 g to about 30 g, about 0.5 g to about 20 g, about 0.5 g to about 10 g, about 0.5 g to about 5 g, about 0.5 g to about 4 g, about 0.5 g to about 3 g, about 0.5 to about 2 g, about 0.5 to about 1.5 g, about 0.5 g to about 1 g, or about 1 g to about 2 g.
- the dose is at least 0.1 g, 0.5 g, at least 1 g, at least 1.5 g, or at least 2 g. In some embodiments, the dose is about 0.1 g, about 0.2 g, about 0.3 g, about 0.4 g, about 0.5 g, about 0.6 g, about 0.7 g, about 0.8 g, about 0.9 g, about 1.0 g, about 1.1 g, about 1.2 g, about 1.3 g, about 1.4 g, about 1.5 g, about 1.6 g, about 1.7 g, about 1.8 g, about 1.9 g, about 2.0 g, about 2.5 g, about 3.0 g, about 3.5 g, about 4.0 g, about 4.5 g, about 5.0 g, about 6.0 g, about 7.0 g, about 8.0 g, about 9.0 g, about 10 g, about 11 g, about 12 g, about 13 g, about 14 g, about 15 g, about
- the dose is provided in an amount of fluid in the range of about 5 mL to about 20 mL, about 5 mL to about 10 mL, about 1 mL to about 20 mL, about 1 mL to about
- the dose is provided in about 1 mL, about 2 mL, about 3 mL, about 4 mL, about 5 mL, about 6 mL, about 7 mL, about 8 mL, about 9 mL, about 10 mL, about 11 mL, about 12 mL, about 13 mL, about 14 mL, about 15 mL, about 16 mL, about 17 mL, about 18 mL, about 19 mL, or about 20 mL of fluid.
- the dose is administered at a rate of no less than 0.1 mL/s, no less than 0.2 mL/s, no less than 0.3 mL/s, no less than 0.4 mL/s, no less than 0.5 mL/s, no less than 0.6 mL/s, no less than 0.7 mL/s, no less than 0.8 mL/s, no less than 0.9 mL/s, or no less than 1 mL/s.
- the hemorrhage is posttraumatic hemorrhage, postpartum hemorrhage, or postoperative hemorrhage. In some embodiments, the hemorrhage is external. In some embodiments, the hemorrhage is internal. In some embodiments, the antifibrinolytic agent is administered within 5 hours, within 4 hours, within 3 hours, within 2 hours, within 1 hour, within 45 min, within 30 min, or within 15 min of the onset of the hemorrhage.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental & Geological Engineering (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
La présente divulgation se rapporte de manière générale à un dispositif d'administration pour l'injection automatique d'au moins deux doses d'un liquide dans un site IM d'un sujet au cours d'au moins deux étapes de fonctionnement différentes. Le dispositif d'administration comprend généralement un corps inférieur logeant au moins deux chambres, un corps supérieur qui peut être disposé amovible sur au moins une partie du corps inférieur pour activer le dispositif d'administration et au moins deux ensembles d'injection, chaque ensemble d'injection étant positionné dans une chambre et chacun pouvant fonctionner pour injecter et administrer un liquide à un site IM.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2022/051623 WO2023077225A1 (fr) | 2021-11-02 | 2022-11-02 | Dispositifs, systèmes et procédés d'administration de médicament |
CA3237172A CA3237172A1 (fr) | 2021-11-02 | 2022-11-02 | Dispositifs, systemes et procedes d'administration de medicament |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163138020P | 2021-01-15 | 2021-01-15 | |
US63/138,020 | 2021-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022150927A1 true WO2022150927A1 (fr) | 2022-07-21 |
Family
ID=82446864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2022/050057 WO2022150927A1 (fr) | 2021-01-15 | 2022-01-14 | Dispositifs, systèmes et méthodes pour l'administration de médicaments |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022150927A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011101351A1 (fr) * | 2010-02-17 | 2011-08-25 | Sanofi-Aventis Deutschland Gmbh | Dispositif d'injection entraîné par ressort avec cartouches jumelles |
WO2015181192A1 (fr) * | 2014-05-28 | 2015-12-03 | Sanofi-Aventis Deutschland Gmbh | Dispositif d'administration de médicament pour l'administration de deux médicaments |
-
2022
- 2022-01-14 WO PCT/CA2022/050057 patent/WO2022150927A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011101351A1 (fr) * | 2010-02-17 | 2011-08-25 | Sanofi-Aventis Deutschland Gmbh | Dispositif d'injection entraîné par ressort avec cartouches jumelles |
WO2015181192A1 (fr) * | 2014-05-28 | 2015-12-03 | Sanofi-Aventis Deutschland Gmbh | Dispositif d'administration de médicament pour l'administration de deux médicaments |
Non-Patent Citations (2)
Title |
---|
CULLIGAN W. BRENT, TIEN HOMER C.: "Tranexamic Acid Autoinjector for Prehospital Care of Noncompressible Hemorrhage", JOURNAL OF TRAUMA: INJURY, INFECTION & CRITICAL CARE, vol. 71, no. 5, 1 November 2011 (2011-11-01), US , pages S501 - S502, XP009538684, ISSN: 0022-5282, DOI: 10.1097/TA.0b013e318232ea1e * |
WRIGHT: "Battlefield administration of tranexamic acid by combat troops: a feasibility analysis", J.R. ARMY MED. CORPS., vol. 160, no. 4, December 2014 (2014-12-01), pages 271 - 272, XP055955742 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220054752A1 (en) | Cap Assembly for a Medicament | |
US11771830B2 (en) | Medicament delivery device and methods for delivering drugs to infants and children | |
AU659374B2 (en) | System and method for rapid vascular drug delivery | |
US4394863A (en) | Automatic injector with cartridge having separate sequentially injectable medicaments | |
US5271744A (en) | System and method for rapid vascular drug delivery | |
US20210228813A1 (en) | Auto-Injector | |
US10850044B2 (en) | Safe auto-needle device | |
EP1878454B1 (fr) | Kit de traitement anti-hémorragique | |
US5695472A (en) | Modular automatic or manual emergency medicine injection system | |
ES2763633T3 (es) | Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida | |
CN104968381A (zh) | 药物输送设备 | |
JPH0460673B2 (fr) | ||
SG189081A1 (en) | Auto-injector | |
EP0071289B1 (fr) | Seringue d'injection automatique | |
ES2886553T3 (es) | Un amortiguador de jeringa para su uso en un dispositivo de inyección | |
WO2007075839A2 (fr) | Injecteur de glucagon pour traitement d'urgence d'hypoglycemie | |
JP6640331B2 (ja) | 骨髄内注射器具 | |
JP6987142B2 (ja) | 薬剤注射デバイス | |
WO2022150927A1 (fr) | Dispositifs, systèmes et méthodes pour l'administration de médicaments | |
CA3237172A1 (fr) | Dispositifs, systemes et procedes d'administration de medicament | |
US20220370718A1 (en) | Devices, systems and methods for medicament delivery | |
US20210361880A1 (en) | Systems, devices, and processes for delivery of therapeutic fluids | |
JP2023520050A (ja) | 注射デバイスと共に使用されるパッチ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22738879 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22738879 Country of ref document: EP Kind code of ref document: A1 |